ArticleNeuromolecular medicine2025
Memory-Enhancing Effects of Dauricine in Swiss Mice: Possible Molecular Interventions Through In Vivo and In Silico Studies.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Antiemetic Efficacy of Nodakenin Through Muscarinic, Dopaminergic, and Serotonergic Receptor Modulation: Combined Experimental and Computational Approach.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bisbenzylisoquinoline alkaloid dauricine (DAU) is known for its neuroprotective effects in animals. This study investigates the memory-enhancing effects of DAU in Swiss albino mice using both in vivo and in silico approaches, focusing on its interaction with the D2 dopamine (DOP) receptor. Behavioral tests, including marble burying, dust removal, and trained swimming, were used to assess cognitive performance, anxiety, and motor coordination. Molecular docking studies revealed that DAU binds strongly to the D2 DOP receptor (6CM4 protein), with a binding affinity of - 7.9 kcal/mol, forming significant hydrogen and hydrophobic bonds. Additionally, the pharmacokinetics and toxicity profiles of DAU were also evaluated. In vivo results showed that DAU improved behavioral performance in a dose-dependent manner, with the DAU-10 group showing significant (p < 0.05) enhancement compared to the control and standard groups. The DAU-10 + DOP-22 combination group also showed remarkable results compared to the standard alone. Pharmacokinetics and toxicity profiles were also assessed, revealing favorable properties but some concerns regarding mutagenicity and immunotoxicity. These findings suggest that DAU, especially when combined with D2 DOP receptor agonists, holds significant potential for memory enhancement and warrants further investigation.
Indexed as
Identifiers
40471498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.